"Research is formalized curiosity. It is poking and prying with a purpose." — Zora Neale Hurston, American author and anthropologist
- Surgical robot for hip replacements
- Research on psychedelic drugs
- A "kill switch" for engineered organisms
- SignalPath acquired
- COVID-19 drugs already in use
- Drug candidate for fighting CRS
- Treatment for children's inflammatory syndrome
- Antibody against COVID variants
September 1, 2021
Image courtesy of Zimmer Biotech
- ST. LOUIS, MO—The EPA awarded a $744,262 grant to Tae Seok Moon, associate professor at the McKelvey School of Engineering, for biotechnology research. Moon’s lab has been working on a “kill switch” for engineered organisms that will self-destruct after completing a specified task, such as cleaning up a pollutant or rooting out and destroying a pathogen in livestock.
- RALEIGH, NC—San Francisco-based Verily will be acquiring SignalPath, a privately held company based in Raleigh that has developed a clinical trial management system (CTMS) that improves the quality and efficiency of conducting clinical research at study sites.
COVID-19 drugs already in use
Antibody against COVID variants
Drug candidate for fighting CRS
PITTSBURGH, PA—Biotech company CytoAgents has a lead drug candidate for treating life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an over-reaction by the immune system that causes systematic inflammation, a common reaction to COVID-19.
Treatment for children's inflammatory syndrome
Share stories, offer suggestions or leave a comment!